The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors
Journal Title: Central European Journal of Urology - Year 2014, Vol 67, Issue 3
Abstract
Introduction Benign prostate hyperplasia and erectile dysfunction affect a significant subset of men. BPH and ED may have the same promoting conditions and are the strong predicting risk factors to each other. A significant number of these patients are bothered by lower urinary tract symptoms (LUTS). Direct correlation of age, sexual dysfunction and LUTS severity has been well documented. Many sexually dysfunctional patients with concomitant BPH receive alpha–adrenergic antagonists and any Phosphodiesterase–5 (PDE5) inhibitor simultaneously. PDE5 inhibitors relieve LUTS symptoms in the course of BPH and reduce independent detrusor contractions. This paper presents the results of clinical trials on the efficacy of PDE5 inhibitors on LUTS, new perspectives on its use and newly–identified side effects. Material and methods The review is based on an internet search of PubMed and Medscape databases. The search terms were as follows: LUTS and ED, BPH and phosphodiesterase–5 inhibitors, LUTS clinical trials, phosphodiesterase–5 inhibitors mechanisms. Results Clinical trials show an epidemiological and pathophysiological relationship between BPH, LUTS and ED. Numerous studies reveal the alleviating effect of phosphodiesterase–5 inhibitors on LUTS, expressed as the reduction of IPSS score, but not followed by a change in Qmax. Opponents raise a link of PDE5 inhibitors with increased risk of melanoma. New studies reveal that phosphodiesterase–5 inhibitors are effective in the treatment of neurological disorders. Conclusions Researches reveal the efficacy of phosphodiesterase–5 inhibitors in LUTS along with an improvement of erectile function. The molecular mechanism of action of such drugs suggests imminent novel applications. Potential benefits will be multidimensional. Unfortunately, interfering with particular molecular mechanism
Authors and Affiliations
Stanisław Wroński
Keywords
Related Articles
- EP ID EP356505
- DOI 10.5173/ceju.2014.03.art20
- Views 50
- Downloads 0
What is the best urinary diversion after laparoscopic radical cystectomy?
Bez streszczenia (Editorial)
The presence of LUTS is not a decisive tool for deciding who should be qualified for prostate biopsy
Editorial.
Knowledge about human papillomavirus and the human papillomavirus vaccine in Belgian students
Introduction The aim of this study was to examine the knowledge of Belgian university students about the human papillomavirus (HPV) and HPV–vaccination. Material and methods During a period of two months we administered...
Getting access in PNL – eyes wide shut
Editorial.
Predicting stone composition before treatment – can it really drive clinical decisions?
Introduction Determination of stone composition is considered to be crucial for the choice of an optimal treatment algorithm. It is especially important for uric acid stones, which can be dissolved by oral chemolysis and...